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formed to determine economic advisability of its applying in Belarus. Methods: 
Markov model with 12-month cycle duration and 10-year time horizon has been 
constructed on the basis of a systematic review of literature, national surveillance 
data, local health services market and drugs market estimation. Four conditions 
were included: stable process, non-fatal event (cardiac infraction or unstable 
angina), surgical revascularization, death. Number of patients with stable angina 
who stayed alive and QALY till the end of the last analyzed cycle of the model has 
been used as a measure of efficiency and utility. One-sided determinate sensitiv-
ity analysis has been conducted. Incremental values have been calculated. Direct 
medical expenses have been evaluated. Value of triple GDP per capita per year (10790 
euro) has been used as threshold. Results: Research showed clinical advantage of 
treatment scheme with ivabradine as compared to “traditional therapy” concern-
ing the amount of patients who stayed alive by the end of the last cycle of model 
(7275 vs. 6421 persons in total population and 8136 vs 6993 in patients with heart 
rate > 70 pbm) and QALY number (77635 vs. 69253 in total population and 84138 vs. 
73031 in patients with heart rate > 70 pbm years). The sensitivity analysis showed 
that in 9.09% of cases ivabradine was the prevailing technology, in 90.91% the cost 
per QALY did not exceed the threshold. The average counted incremental cost per 
QALY was 3836 Euro. ConClusions: The analysis showed the pharmacoeconomic 
acceptability of ivabradine use by patients with stable angina with left ventricular 
systolic disfunction and heart rate ≥ 70 bpm at prescription of the medication in 
optimal dosage which ensures minimal market value of the medication.
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objeCtives: Aortic valve replacement (AVR) is the most common heart valve opera-
tion, accounting for a conspicuous part of all valve surgery performed in the elderly. 
Prolonged aortic cross-clamping times are an independent risk factor for worse out-
comes. Perceval S is a new aortic valve which is implanted without need for sutur-
ing and a collapsed profile, thus allowing a significant reduction of cross-clamping 
times. Methods: A patient-level simulation model fully coded in WinBugs was 
updated and extended to predict lifetime effectiveness and costs of concomitant 
AVR procedures associated with this new valve in France and UK, as compared to 
traditional valve implants, from the cost perspective of the third party payer. Two price 
scenarios were evaluated, one in which the sutureless valve is sold at the double, and 
one at the triple price of its comparator. Unit costs and health state-specific utilities 
were retrieved from official and literature sources. Future costs and outcomes are 
discounted at a yearly 3.5% rate. Uncertainty is evaluated through the incorporated 
probabilistic sensitivity analysis and deterministic threshold analyses. Results: The 
model predicts that on average the use of the Perceval S valve instead of traditional 
sutured valves would yield incremental 0.21 LYs (0.16 QALYs) per patient, with an 
associated saving of about 5,100 € and 4,400 £ in France and UK, respectively, in 
the first scenario, and of 2,600 € and 1,900 £, in the second. Deterministic threshold 
analysis indicates that the sutureless valve would remain averagely dominant as long 
as its price does not exceed 4.1 and 3.8 times that of the traditional valve, in France 
and UK, respectively. ConClusions: The sutureless valve offers the opportunity to 
improve outcomes in concomitant AVR at a reduced cost to the third party payers.
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objeCtives: Health status plays an important role in individuals’ labour supply 
decision. Chronic diseases, such as cancer, diabetes mellitus, cardiovascular disease, 
mental illness and disabilities are reported to have strongest effect on individual 
transitions on the labour market. Among them, cardiovascular disease (CVD), in addi-
tion to being the leading cause of death, is likely to affect individuals’ employment 
decision. The aim of this study is to investigate the impact of clinically diagnosed car-
diovascular disease on labour supply, taking account of the observed and unobserved 
factors that influence the risk of cardiovascular disease and labour force participa-
tion. Methods: Study subjects were randomly selected from Gazi University general 
internal medicine outpatient clinic. Demographic, health and employment status 
data have been compiled for five hundred and fifteen study subjects who applied to 
the clinic between December 2012 and February 2013. The bivariate probit method 
has been utilized to investigate the impact of incidence of cardiovascular disease on 
employment status. Results: Empirical results indicate that cardiovascular disease 
have a strong negative impact on labour market outcomes, particularly for men, and 
that education level, gender, hypertension have significant indirect effects on labour 
force participation. Analysis results suggest that there is a correlation between the 
labour force participation and the incidence of cardiovascular disease, revealing that 
single equation models might be misspecified. ConClusions: As cardiovascular dis-
ease has a significant negative impact on employment status, public health programs 
need to address this issue and provide treatment strategies and prevention efforts to 
alleviate the destructive impact on societal productivity.
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objeCtives: To define hospital and post discharge-related resource use for patients 
undergoing Transcatheter Aortic Valve Implantation (TAVI) and conventional Aortic 
Valve Replacement (AVR) surgery within a single UK hospital. Methods: A local 
A Markov model was developed to predict the occurrence of myocardial infarction, 
stroke, coronary revascularization and death. The model considers a lifetime horizon 
and a 3.5% discount rate. Clinical inputs were derived from the JUPITER trial and 
from a cohort of the MESA study fulfilling JUPITER inclusion criteria. Event costs 
were obtained from the literature. Rosuvastatin 20mg cost incorporates a discount to 
reflect the introduction of generics within a maximum of 5 years. Results: Coronary 
calcium score determination and subsequent primary prevention in individuals 
with a score exceeding 100 dominates no treatment. Implementing primary preven-
tion in those patients with positive score, and not just those with score above 100, 
implies a willingness to pay around 40,000€ per QALY. Finally, primary prevention in 
all individuals is not cost-effective when compared to primary prevention in those 
with positive calcium score as it is associated with a cost per QALY of more than 
600,000€ . ConClusions: Determination of coronary calcium score is cost-effective 
as it allows to identify those patients that will benefit most from primary preven-
tion. Primary prevention in patients with calcium score greater than 100 should be 
implemented. The implementation of this strategy in other patients with positive 
calcium score depends on the willingness to pay for a QALY.
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objeCtives: Aortic valve replacement (AVR) is the most common heart valve 
operation, accounting for a conspicuous part of all valve surgery performed in 
the elderly. Prolonged aortic cross-clamping times are an independent risk factor. 
Perceval S is a new aortic valve which is implanted without need for suturing and a 
collapsed profile, thus allowing a significant reduction of cross-clamping times and 
to expand the pool of patients operable with mini-invasive aortic valve replacement 
(MiAVR) among isolated AVR candidates. Aim of this simulation study was to predict 
costs and outcomes of isolated AVR procedures associated with this new valve in 
Germany, as compared to traditional valve implants, from the cost perspective of 
the third party payer. Methods: A previously published probabilistic, patient-level 
simulation model fully coded in WinBugs was updated with new clinical data and 
the evaluation extended to evaluate lifetime cost-effectiveness from the perspective 
of the third party payer. Unit costs and health state-specific utilities were retrieved 
from official and literature sources; the price of the sutureless valve is hypothesised 
twice as much as for traditional valves. Future costs and outcomes are discounted 
at a yearly 3.5% rate. Results: The model predicts that on average the use of the 
Perceval S in MiAVR instead of traditional sutured valves in full sternotomy among 
isolated AVR candidates, would yield incremental 0.29 LYs (0.20 QALYs) per patient, 
with an associated saving around 3,500 € , thus representing a dominant option 
when compared to traditional surgical AVRs. In concomitant procedures, on aver-
age the use of the Perceval S valve instead of traditional sutured valves is expected 
to yield incremental 0.21 LYs (0.16 QALYs) per patient, with an associated saving of 
over 4,400 € , also representing a dominant alternative. ConClusions: Sutureless 
valves may improve outcomes in AVR at a reduced cost to the third party payers.
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objeCtives: To conduct a systematic review of cost-effectiveness studies of newer 
oral anticoagulants for stroke prevention in atrial fibrillation versus warfarin and 
understand its implications for policy and for further research. Methods: We 
searched DARE, Cochrane, NICE, Tufts, NHS EED, Science Direct and PubMed through 
May 2013 to identify studies of oral anticoagulants dabigatran, rivaroxaban and 
apixaban versus warfarin for stroke prevention in non-valvular atrial fibrillation 
in patients at a moderate-to-high risk of stroke initiating anticoagulation for/near 
lifetime using either a societal or health care perspective. A separate analysis was 
performed for ISPOR abstracts. Results: Ten studies were identified, most based 
on one randomized trial per therapy, 3 reported an ICER above commonly accepted 
WTP levels. ICERs ranged from $9,099–$86,000 for dabigatran and $3,190–$55,757 for 
rivaroxaban. Apixaban was found to be cost-effective $11,400–$24,312. Upon PSA, 
dabigatran was cost-effective 40% to 98%, apixaban 44.1% to 60%, and rivaroxaban 
2.1% to 80% of the time, for the lowest reported WTP. Variations in ICERs occurred 
between studies that used the same efficacy data. Key variables influencing vari-
ations include differences in costs; assumptions for INR monitoring and utiliza-
tion of health care resources; and the probabilities of adverse event. Effectiveness, 
compliance, adverse events and INR management were derived from clinical tri-
als. Additional data from recent abstracts reported similar trends. ConClusions: 
For this indication, novel agents seem to be cost-effective alternatives to warfarin, 
despite variations across countries. However, cost-effectiveness may depend on: 
prices of medicines in each country; the proportion of actual patients’ time within 
the INR therapeutic range; and the actual real-world effectiveness, safety, and utili-
zation of these therapies. More head-to-head RCTs and pragmatic trials are required. 
Future cost-effectiveness studies of these new therapies should be periodically 
repeated during the lifecycle of medicines under real-world utilization and should 
also incorporate budget impact analysis.
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objeCtives: Cost-effectiveness and cost-utility analysis of ivabradine use in 
patients with stable angina with left ventricular systolic dysfunction has been per-
